Peptides
CJC-1295
Growth Hormone Releasing Hormone Analogue
Category
GH peptide
Half-life
No DAC: ~30 min | With DAC: ~8 days
Typical dose
No DAC: 100 mcg | With DAC: 2mg
Frequency
No DAC: 3× daily | With DAC: 1× weekly
Route
Subcutaneous injection
Mechanism
CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone in a pulsatile pattern. Available in two forms: without Drug Affinity Complex (DAC) — short half-life, pulsatile GH release mimicking natural patterns; and with DAC — extended half-life via albumin binding, producing sustained GH elevation. Typically stacked with a GHRP such as ipamorelin for synergistic GH release.
Research summary
CJC-1295 without DAC produces pulsatile GH release with minimal impact on cortisol or prolactin — favorable for research protocols. With DAC produces sustained GH elevation useful for baseline GH optimization. Pre-sleep dosing aligns with the natural GH pulse during slow-wave sleep.
Storage
Lyophilized: −20°C. Reconstituted: 2–8°C up to 4 weeks.
Key studies
Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. JCEM. DOI: 10.1210/jc.2005-2357
Frequently asked questions
What is the difference between CJC-1295 with and without DAC?
Without DAC: 30-minute half-life, produces a natural pulsatile GH release. Dosed 3× daily or pre-sleep. With DAC: 8-day half-life via albumin binding, produces sustained GH elevation. Dosed once weekly.
Should I stack CJC-1295 with ipamorelin?
CJC-1295 + ipamorelin is one of the most common GH stacks in research. CJC-1295 stimulates GHRH, ipamorelin stimulates GH release via a separate receptor pathway. Together they produce a synergistic GH pulse greater than either alone.
For research use only. Not intended for human consumption. Not medical advice. Consult a licensed physician before use.